VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
VolitionRx Limited, a Delaware corporation trading on NYSE American under the symbol VNRX, filed this Current Report on March 31, 2026. The filing serves to announce financial results and business updates for the quarter and fiscal year ended December 31, 2025. A conference call to discuss these results was scheduled for April 1, 2026.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text provided.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of a press release containing the results for the period ended December 31, 2025.
Guidance, Outlook, and Risks
Management commentary, specific guidance, outlook, risks, contingencies, and unusual items are not detailed in the body of this Form 8-K. The document states that such information is contained within the press release (Exhibit 99.1) and notes that the information is "furnished" rather than "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the quarter and year ended December 31, 2025.
- Verify the details of the conference call held on April 1, 2026, for management's commentary on the results.
- Confirm the company's liquidity position and debt levels as disclosed in the full press release.
- Check for any forward-looking statements or updated guidance provided in the press release.